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ABSTRACT

Development of CXCR4 Inhibitors for Topical Treatment of Psoriasis
Suthida Boonsith, Ph.D.
University of Nebraska Medical Center, 2017
Supervisor: David Oupický, Ph.D.
Psoriasis is a chronic inflammatory skin disease that is often associated with
systemic comorbidities and impaired skin barrier function. There are several treatment
options including topical treatment with immunosuppressants, phototherapy, and systemic
therapies using small molecules and biological agents. However, none of them can be
regarded as a perfect solution due to their toxicity during chronic use. Recently, the
CXCR4/SDF-1 axis was found to play an important role in the pathogenesis of psoriasis.
AMD3100, a small molecule CXCR4 antagonist can selectively bind to CXCR4 and inhibit
skin inflammation, reduce angiogenesis and

infiltration of inflammatory cells.

Unfortunately, AMD3100 can only be administered systemically.
In this study, we aimed to develop CXCR4 inhibitor that can be applied topically in
psoriasis as a way of reducing overall systemic toxicity of CXCR4 inhibition. We developed
PAMD, a polycation based on AMD3100, as a topical drug to treat psoriasis. PAMD offers
a great platform for chemical modification, drug combination, and the ability to form
nanocarriers. Psoriasis is a skin disease therefore, it is desirable to deliver PAMD via a
topical route to target the disease locally and improve safety and patient compliance.
Stratum corneum (SC) is the foremost layer of skin, which acts as the main barrier to
protect internal organs and limit the delivery of most drug molecules. Various attempts
have been reported to increase skin penetration, including both passive and active
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methods. The mechanism of skin absorption is dependent on size, charge, and partition
coefficients of the penetrant. Based on previous reports on the role of hydrophobicity and
charge on skin penetration of polymers, our approach relied on modifying the PAMD with
citraconic anhydride for a negative charge and oleic acid for lipophilicity.
The best performing negatively charged PAMD demonstrated low toxicity in
HaCaT cells in vitro, and high retention and deep penetration in both healthy and psoriatic
skin models. The favorable level of penetration may be due to the acidic skin environment
and the intercellular transportation within SC, facilitated by the attraction of the polymer
and diffusion respectively. IMQ-induced psoriasis mouse model was attenuated by a
topical application of PAMD, PAMD.COO-, and subcutaneous injection of AMD3100. This
observation provided evidence supporting that blockade of CXCR4/SDF-1 cascade
reduces skin inflammation related to the decreased mRNA levels of pro-inflammatory
cytokines IL-1β, IL-6, and TNF-α. The topical application of CXCR4 antagonistic polymers
exhibited comparable in vivo therapeutic effects as systemic administration of AMD3100.
Moreover, the penetration of the polymer had no influence on anti-psoriatic activity in mice.
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CHAPTER 1
INTRODUCTION

1.1 Skin Physiology
Skin is the largest organ in the body and functions as a protective barrier. Skin is
divided into three main layers: epidermis, dermis, and subcutaneous tissue (hypodermis).
Epidermis consists of two distinct parts: the viable epidermis (70% water), and the stratum
corneum (SC) (13% water) (Fig 1.1).
SC plays a crucial role in maintaining a physical barrier and functions to prevent
water loss and foreign substance penetration. Due to the highly lipophilic nature of SC,
hydrophobic substances can easily enter the SC, but not viable epidermis. SC is
approximately 10-20 μm thick, made of dead cells (corneocytes) filled with keratin, and
embedded in tightly arranged lipid bilayers. The intercellular lipids are made of long chain
ceramides, free fatty acids, triglycerides, cholesterol, and sterol/wax esters.
Epidermis is composed of 10-20 layers of cells, mainly keratinocytes, and some
dendritic antigen presenting cells named Langerhans cells (LCs). Keratinocytes are in the
stratum basale and continuously divide to produce new cells. The new keratinocytes move
to the upper layer, transition to corneocytes that have lost their nuclei, and eventually shed
from the SC.
Dermis is largely composed of collagenous connective tissue, blood vessels,
nerves, several immune cell types, and appendages (hair follicles, sweat glands, and
sebaceous glands). The dermis provides most of the skin’s mechanical resistance and
elasticity [1, 2].
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Fig 1.1 Skin physiology and histology. Skin is composed of three layers: epidermis (50100 μm), dermis (1-2 mm), and hypodermis (1-2 mm). Adapted from [3]
Drugs can be delivered to the skin for the treatment of skin diseases or through
the skin for the treatment of systemic diseases. Viable epidermis is a common target site
for anti-inflammatory agents, antiproliferative agents, vaccines, and experimental gene
therapy due to the abundance of keratinocytes and dendritic cells. Dermis is also the target
site for local anesthesia, analgesics, and drugs that need systemic absorption since this
layer is rich in vasculature which allows for rapid transport into the blood.
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1.2 Psoriasis pathology
Psoriasis is a chronic inflammatory skin disease that affects all ages and sexes.
The prevalence in different populations varies from 0.09% to 5.1% [4] or approximately
2% to 5% of the world’s population [5]. Psoriasis is likely the most prevalent immunemediated skin disease in humans. The cause of psoriasis is not well understood, but there
are several factors that contribute to the initiation phase of the disease, including heredity,
injury and trauma, infection, stress, environment, and medications. The major clinical
manifestations of psoriasis include characteristic skin lesions, including chronic plaque (or
psoriasis vulgaris), guttate psoriasis, and generalized or localized (pustular) psoriasis. The
chronic plaque is the most common subtype and can involve multiple areas of the body
[6].
Psoriasis is characterized by hyperproliferative keratinocytes in the interfollicular
epidermis, along with abnormal terminal differentiation, dilation, hyperplastic blood
vessels, and inflammatory infiltration of leukocytes into the dermis. The skin psoriatic
patches are typically red, itchy, and scaly. The maturation of keratinocytes from basal layer
to cornified layer in normal skin usually takes 28-30 days. In psoriatic lesions, the
maturation is shortened to 3-5 days [7]. This shortened maturation is associated with
massively disrupted terminal differentiation of keratinocytes and the retention of partially
differentiated keratinocytes that cause the appearance of parakeratosis. Numerous
proteins are down-regulated in these lesions, including keratin 1 and 10, which are
responsible for terminal differentiation. Moreover, the production of extracellular lipid is
reduced [8].
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Massive infiltration of inflammatory cells, dendritic cells and T cells are observed
in psoriatic lesions. Numerous T cell phenotypes, for instance, CD4 (in dermis) and CD8
(in epidermis) have been identified in varying amounts [9]. The vascular endothelial growth
factor (VEGF), a major driver of inflammation-induced angiogenesis, is upregulated in
lesioned epidermis and plasma of psoriasis patients and its levels correlate with disease
severity. The greater the number of dilated dermal blood vessels the greater erythema
exhibited in psoriasis [10].
The classic histological features of psoriasis are demonstrated by hematoxylin and
eosin (H&E) staining (Fig 1.2) The epidermis is greatly thickened (acanthosis) with
elongation of the rete ridges as keratinocytes hyperproliferate and quickly move through
the epidermis. There is an increased SC hyperkeratosis with keratinocyte nuclei retention
(parakeratosis). The retention of keratinocyte nuclei in the SC is due to the abnormal
differentiation of skin cells. Infiltrated neutrophils are observed in the epidermis and form
collections called Munro’s microabscesses. Then in the dermis, there is an abundance of
inflammatory infiltrate consisting mainly of dendritic cells, macrophages, and T cells that
consequently produce pro-inflammatory cytokines.

Fig 1.2 Psoriatic lesion and histological features of human psoriatic skin [3]
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1.3 Immune mechanisms in psoriasis
The role of the immune system in psoriasis pathogenesis has been studied for
several decades. The imbalanced interactions of innate and adaptive immune systems in
the skin are believed to cause inflammatory skin conditions. Innate immune cells (dendritic
cells, keratinocytes, macrophages, natural killer T-cells) induce a pro-inflammatory
cytokine cascade that drives the adaptive immune response. Researchers have found a
complex and long list of cytokines present within psoriatic plaques and the current focus
is on TNF-α, IL-23, and IL-17.
Dendritic cell (DC) subsets have been found in the epidermis (LCs) and dermis
(dermal dendrocytes) of psoriatic lesions. LCs possess ATPase activity, that may play an
anti-inflammatory role by degrading pro-inflammatory ATP [11]. In contrast, a reduced
number of LCs are seen in the anti-TNF-α treated psoriatic lesions [12]. The plasmacytoid
DCs produce high levels of IFN-α and can be activated by the TLR-7 agonist, Imiquimod
[13]. IFN-α triggered psoriasis also supports the clinical observation that patients receiving
IFN-α injections experience a flare up of psoriatic lesions at the site of injection [14]. The
number of dendritic cells is increased in psoriasis plaques and can influence the behavior
of T cells. DCs link innate and adaptive immune responses by acting as antigen presenting
cells. The activated DCs in the skin secrete cytokine mediators such as IL-12 and IL-23
that drive the differentiation of helper T cells into Type 1 (Th1) and Type 17 (Th17). Th1
and Th17 released cytokines including IL-17 and IL-23. Then IL-23, IL-17, IL-22, IL-1β, IL6, and TNF-α interact as a network to activate keratinocyte and promote keratinocytes
proliferation.
The above set of observations defined the presence and significance of T cells in
normal healthy skin as well as in pre-psoriatic skin. It has been estimated that there are
approximately 2x1010 T cells in the entire skin surface or 1x106 T cells/cm2, which is twice
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the total number of T cells in circulation. This understanding demonstrates that the large
pool of T cells in the skin can initiate immune reaction without T cell recruitment from the
blood [15]. The T cells appear to be pre-programmed with a Th1 cytokine secretion and
create psoriatic lesions in immunodeficient mice [16].
Th1 cells were originally considered to be the main mediator of immune response
in psoriasis [17, 18]. The new paradigm form Th17 was recently discovered because of
early clinical trial results indicating that the antibody which targets the p40 subunit can
reduce psoriasis lesions [19]. The p40 subunit is shared by IL-12 and IL-23, which also
have their own unique subunit p35 and p19 respectively. Evidence has shown increased
levels of p19 and p40 mRNA in psoriatic lesions, despite no difference in p35 levels [20].
Therefore, IL-23 drives the pathogenesis of psoriasis. Th17 differentiation is dependent
on IL-23 and crucial for the secretion of IL-17, IL-12, IL-22, and IL-9, which directly promote
the inflammatory response of keratinocytes. As a result, IL-23 and Th17 were proposed
as a new combination that drives immune activation and chronic inflammation [21]. IL-17
is overexpressed in patients with a variety of allergic and autoimmune diseases and
promotes the accumulation of neutrophils [22].
The relationship among T cell subsets and cytokines is demonstrated in Fig 1.3.
Keratinocytes, NK T-cells, DCs, and macrophages are triggered by stimuli to produce
cytokines that initiate DC activation. The activated DCs subsequently produce IL-12 and
IL-23. IL-12 induces a Th1 immune response, characterized by the production of IFN-γ
and TNF-α. Whereas IL-23 induces a Th17 immune response, characterized by the
production of IL-17 and IL-22. These cytokines then promote the changes in epidermal
keratinocytes, including the upregulation of pro-inflammatory cytokines, increases in
mitotic activity of keratinocytes, production of growth factors that promote angiogenic
response, and provide a positive feedback loop to macrophages. The crosstalk between
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activated fibroblasts, infiltrating leukocytes, and epidermal keratinocytes enhances the
inflammatory process and keratinocyte proliferation, and leads to the development of
psoriasis. Macrophages can also be triggered by TNF-α to produce additional cytokines,
which further stimulate dermal angiogenesis by promoting the migration, survival, and
proliferation of endothelial cells, resulting in the formation of erythematous vascular
plaques [23-25].

Fig 1.3 Overview of potential interactions between immune effector cells, cytokines and
pathways that contribute to the immunopathogenesis of psoriasis. The innate immune
system provides an early-response mechanism against harm to the host. Dendritic cells
bridge the gap between innate and adaptive immunity and induce the proliferation of T
cells. T cells contribute to the pathogenesis of psoriasis. Adapted from [26-28]
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1.4 Psoriasis crosstalk
Although psoriasis does not cause death, it does lead to a physiological burden
and considerable psychological pain. Several studies showed the association of psoriasis
with multi-system manifestations, including arthritis, Crohn’s disease, cardiovascular
diseases [29, 30], depression, hyperlipidemia, type 2 diabetes mellitus, and obesity [31,
32]. Moreover, some studies demonstrated psoriasis can increase the risk of death and it
was highest for cardiovascular disease [33]. The relationship between psoriasis and
systemic comorbidities is not fully understood but the sharing of inflammatory mediators
may provide the link [34, 35].
It is important to note that skin diseases can also alter skin barrier integrity. In
psoriasis, skin thickness is increased, especially in the epidermis layer and the impairment
of the skin’s barrier function is well documented [36-39]. Ceramides, the main polar lipids
in SC, were found to be decreased in lesioned skin of psoriatic patients [40]. The lower
levels of ceramides were correlated with increased transepidermal water loss (TEWL) [41]
and that contributed to the severity of psoriasis [42]. TEWL is an indicator of SC barrier
function. The increase in TEWL indicates reduced water retention capacity and is
characterized by abnormal cohesiveness and dryness. Furthermore, the disturbance of
barrier integrity or function could initiate the cascade that subsequently triggers an
inflammatory response in the dermis and leads to the development of psoriasis (Fig 1.4)
[36], [43, 44]. Thus, a topical application of agents that can restore skin homeostasis could
be useful for the prevention and treatment of skin disorders associated with permeability
barrier dysfunction [45].
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Fig 1.4 Psoriasis crosstalk; the occurrence of psoriasis, triggers the changes in skin
structural and physiological functions. Far more than that, psoriasis is often present with
inflammatory responses in other organs. Adapted from [37]
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1.5 Treatment options
In the late 1960s, psoriasis was thought to be caused by the abnormal proliferation
of keratinocytes and subsequent differentiation. Thus, anti-proliferative agents such as
methotrexate, anthralin, and coal tar were selected as treatments to inhibit keratinocyte
proliferation. In addition, agents that can normalize abnormal growth and differentiation in
keratinocytes, like vitamin D analogs and retinoids, have been used to restore epidermal
homeostasis. Later in the late 1970s, a clinical observation was made that
immunosuppressive agent cyclosporine A, which was primarily used as an anti-rejection
drug in organ transplantations, unexpectedly cleared psoriatic lesions. Thus, the ultimate
underlying cause of psoriasis has been attributed to a disorder of the immune system [46,
47].
Psoriasis plaques can persist for years if not treated and the disease is entirely
reversible even after the appropriate therapy. According to the disease severity and
response rate, there are a wide range of treatment options that can be applied to the
affected area. Clinical classification of psoriasis ranges from mild (where less than 5% of
the body’s surface area is affected), to moderate (5 – 10%), to severe (greater than 10%)
[5]. The disease score can also be assessed by a trained healthcare practitioner using the
Psoriasis Activity and Severity Index (PASI) score. This approach ranks the severity and
area of erythema (redness), induration (thickness), and desquamation (scale) of the
plaques in different body site. The treatment is considered successful if it shows 75%
improvement from the baseline (reported as PASI75).
It is highly recommended that patients with mild or moderate psoriasis use a topical
treatment due to their low systemic toxicity and ability to target the affected area.
Phototherapy is useful for patients with widespread disease who have moderate to severe
psoriasis. Severe cases of psoriasis are often treated with systemic agents, but are
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expensive and can be toxic. In many cases, systemic treatment and phototherapy are
more effective options, but the duration of a treatment is restricted. For example,
phototherapy may increase the risk of skin cancer [48], methotrexate can induce liver and
bone marrow toxicity [49, 50].
Topical therapy has been widely used in almost all psoriasis patients as a single
or adjuvant therapy to reduce the amount of phototherapy or systemic treatments required
to achieve satisfactory control, especially for moderate and severe conditions. Their
convenience, safety, flexibility, efficacy, and low cost help to increase patients’
compliance. Moreover, topical drugs can be formulated into various forms such as
powders, solutions, sprays, suspensions, emulsions, ointments, creams, pastes, gels, and
patches.
Several topical therapeutic agents are available for the treatment of psoriasis, but
none of them can be regarded as an ideal drug. Topical corticosteroids demonstrate
clinical improvement in various dermatoses including psoriasis and have been widely used
for several decades, mainly due to their immunosuppressive, anti-inflammatory, and
antiproliferative properties. However, a long-term and excessive use of topical
corticosteroids can cause side effects and the efficacy of treatment can be reduced over
time [51, 52]. Therefore, rotational therapy or an intermittent treatment schedule, are
generally advised to improve the safety profile over longer periods and produce a
satisfactory clinical outcome.
Besides small molecule therapeutic agents, highly specific biologics have been
developed to block T cell function at various steps, including preventing the activation and
proliferation of T cells (alefacept), inhibiting lymphocyte activation and migration into
inflamed tissues (efalizumab), and interfering with the binding of cytokines to their
receptors expressed on immune cells (adalimumab) [23]. Although biologics lack the
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adverse effects shown in some conventional therapies, they have their own set of side
effects such as reactivation of latent infections.
Current available treatment for psoriasis in enlisted in Table 1.1
Table 1.1 Classification of psoriasis drugs in clinical uses

Topical therapy
•Emollients, Corticosteroids, Retinoids, Dithranol
•Ketatolytics (salicylic acid, urea), Vitamin D analogues (calcitriol, calcipotriol)
•Calcineurin inhibitor (tacrolimus)

Phototherapy

•Narrowband UVA,

Broadband UVB,

Psoralen-UVA (PUVA)

Systemic therapy
•Metrotrexate, Cyclosporin A, Fumaric acid esters, Hydroxyurea

•Biological targeting molecules; anti-IL12/23 (Stelara, ustekinumab),
anti-TNF (Humira, adalimumab), anti-IL17 (secukinumab)

13
1.6 CXCR4/SDF1 axis in psoriasis
CXCR4 is a highly conserved transmembrane G-protein coupled chemokine
receptor that exclusively binds its ligand SDF-1. Stromal cell-derived factor 1 (SDF-1, or
CXCR-12) has been found to have angiogenic activity and its primary receptor, CXCR4,
is expressed by endothelial cells as well as monocytes and lymphocytes. The
CXCR4/SDF-1 axis is usually involved in tumor progression, angiogenesis, metastasis,
and survival [53]. SDF-1 functions as a chemotactic cytokine that direct the movement of
circulating leukocytes to the sites of inflammation. The interaction between SDF-1 and
CXCR4 causes the activation of various downstream signaling pathways and cytokine
production. It is reported that AMD3100, a specific CXCR4 antagonist, can competitively
bind to CXCR4, thus inhibiting the signaling cascades initiated by CXCR4/SDF-1 axis [5456].
In inflamed skin, CXCR4 is highly expressed on activated cutaneous DCs and
SDF-1 is produced by the lymphatic vessels after antigen exposure. The inhibition of
CXCR4 significantly impairs migration of cutaneous DCs and reduces contact
hypersensitivity responses in mice [57].
Silvana et al. found that there was an expression of CXCR4 cells in human
psoriatic lesion and the upregulation of mRNA levels of CXCR4 and SDF-1 were found in
both human psoriasis and experimental mouse models of chronic psoriasis-like skin
inflammation (Fig 1.5). A systemic treatment with CXCR4 antagonist AMD3100 showed
anti-inflammatory and anti-angiogenesis effects by CXCR4 blockade (Fig 1.6). AMD3100
blocked the migration of CXCR4-expressing cells (T cells, DCs, and macrophages) into
the inflamed area resulting in a reduction of epidermal thickness and dermal inflammatory
infiltrates. In the K14.VEGF-A transgenic mouse model, VEGF-A expression was
correlated to the severity of psoriatic condition and the CXCR4 receptors that were
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expressed by cutaneous blood vessels. The blockade of CXCR4 reduced inflammationinduced angiogenesis by lowering the number of blood vessels present in psoriatic lesions
(Fig 1.7) [58].
1

2

Fig 1.5 Up-regulation of CXCR4 and SDF-1 in psoriatic skin (1) Human (2) Imiquimod
(IMQ) induced psoriasis mouse model, adapted from [58]

1

2

Fig 1.6 Systemic treatment of psoriasis with AMD3100 lead to the reduction of (1) chronic
skin inflammation and (2) inflammatory angiogenesis, adapted from [58]
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CXCR4
Location
s

Inhibition
of CXCR4

Fig 1.7 CXCR4/SDF-1 axis in psoriasis. Circulating CXCR4 positive cells (leukocytes) are
chemoattracted to the inflamed tissue by SDF-1. This attraction can be blocked by CXCR4
antagonist (AMD3100), therefore reduce chronic skin inflammation.
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1.7 Polymeric AMD3100 (PAMD)
PAMD, a polymeric AMD3100, has been developed and is currently used as a
gene delivery vector (polyplexes) for cancer cell invasion inhibition [59]. This polymer acts
as an active drug and has the potential for chemical modification to control the efficacy
and toxicity of the molecule [60, 61]. Chemical modification is possible because not all of
the amine groups are required for the binding of CXCR4 receptor in order to exhibit
pharmacological function and the overall charge can be reduced without compromising
potency (Fig 1.8) [62].
Synthetic polymers have been used for delivering therapeutic agents, including
small molecules, proteins, and genes. The polymers can be fabricated into nanosized
carrier and provide tunable chemical and physical features for controlled release, thereby
improving the pharmacokinetics and pharmacodynamics of drugs [63, 64]. This potential
offers a great platform to achieve effective drug delivery in the skin with PAMD.

Fig 1.8 Structure of AMD3100 and PAMD. AMD3100 contains six secondary and two
tertiary amines, providing the opportunity for chemical modification.
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1.8 Topical drug delivery and penetration enhancement
The administration of drugs to the skin has been practiced for centuries to treat
local diseases. This route holds several advantages over other routes such as painless
administration, avoidance of gastric degradation, and first-pass metabolism of drug
molecules in addition to superior patient compliance. However, the major limitation of this
route is that the skin is typically only permeable to small lipophilic drugs. The poor
penetration of hydrophilic or charged molecules across the skin is primary due to the
lipophilic nature of the SC and its low water content.
The permeation of a drug through the SC is largely dependent on the partition
coefficient of the drug molecule. Drugs that can passively move across skin typically have
molecular weights less than 500 Da, Log P 1-3, aqueous solubility ≥ 1mg/ml,
hydrodynamic radius ≤ 2 nm with a dose of approximately 10-40 mg/day. Ideally, a drug
must possess both aqueous and lipid solubility. A highly hydrophilic drug will not be able
to transfer into SC layer. In contrast, a highly lipophilic drug will form a depot in the SC
layer [65].
The size and charge of drug molecules play an important role in percutaneous
absorption. An increased molecular weight causes a decrease of the transport. The pH of
the formulation is also an important factor that can influence the barrier properties of the
skin, in addition to its influence on the ionic state of the drug. Enhanced percutaneous
penetration was reported at pH lower than 4 and higher than 10 due to the extraction of
the insoluble fraction of keratin. The electrical impedance of the skin was also decreased
at pH lower than 3 and higher than 9 [66].
Most likely, skin diseases influence the cutaneous absorption of drugs. It has been
reported that when the skin barrier is impaired, macromolecules can easily come into
contact with keratinocytes and fibroblasts and increase cutaneous absorption [67-70].
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Drug molecules can be transported into the skin by three different routes:
intracellular (transcellular), intercellular, and follicular (hair follicles and sweat pores) (Fig
1.9). Intracellular is the shortest route, but the drug must cross through both lipid structure
and the cytoplasm of the dead keratinocytes which causes significant resistance to the
permeation. The presence of appendages provides additional pathways even though it
only accounts for 0.01% of the skin’s surface [71]. Recently, there is evidence showing
that follicular penetration may be an important pathway for the penetration of topically
applied chemicals [72, 73].

Fig 1.9 Drug penetration routes across SC. The penetration of drugs into the deeper
regions of skin is controlled by the anatomical properties of skin (skin type and skin
condition), drug features, and the formulation features. Adapted from [74]
The successful topical application of therapeutic drugs depends on the permeation
of drugs across the skin, reaching specific target tissues, and retaining therapeutic levels
throughout the duration of use. Conventional transdermal delivery is generally limited by
the barrier properties of the outermost skin layer. Several research groups have explored
and examined various enhancement methods to overcome skin barrier and increase drug
delivery into the skin. The transdermal drug delivery technology can be classified into two
categories: passive and active methods. Passive methods include the utilization of
chemical permeation enhancers and formulaic approaches. Meanwhile, active methods
require an external source of energy to enhance skin permeability of the drugs [75].
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1.8.1 Chemical enhancement
The passive penetration can be achieved by several compounds with a variety of
enhancement mechanisms such as (1) increasing the interaction with polar head groups
of lipids leading to packing lipid disturbance, (2) increasing water content between lipid
bilayers (hydration), (3) increasing the drug solubility and the improvement of its partition
coefficient, and (4) extraction of SC lipids. Ethanol is the most commonly used solution in
transdermal formulations. Ethanol is capable of increasing the drug solubility and
extracting skin lipids and proteins (increase the porosity of SC). Propylene glycol is the
most frequently used co-solvent in dermatology and usually is combined with oleic acid
for a greater penetration effect. Surfactants are used as emulsifiers to solubilize lipophilic
drugs and SC lipid. The unsaturated fatty acids, especially oleic acid, has been described
many times in the literature due to the potential to disturb the packing lipids in bilayers
[76].
1.8.2 Nanocarriers
Nanocarriers are another technology used to improve loading, protection, targeting
and controlled release of therapeutic agents. In dermatological application, nanocarriers
show properties that improve drug penetration across the SC at a reduced dose with few
side effects [77]. Nanocarriers for skin application can be categorized into 3 main
subtypes: lipid based systems, surfactant based systems, and polymer based systems
(Fig 1.10).
Lipid based nanoparticles are known for their excellent adhesion, skin hydration,
and occlusion properties. The permeation through the skin is due to the flexibility of lipids
that allows them to squeeze through SC channels. Liposomes are built from cholesterol
and

natural

non-toxic

biocompatibility [78].

phospholipids

and

therefore

provide

biodegradability,
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Surfactant based nanoparticles can be formulated with a wide variety of
amphiphilic surfactant molecules that spontaneously aggregate in aqueous medium.
Surfactants are characterized by hydrophilic heads and hydrophobic tails. Micelles are
formed through the self-assembly of block copolymers and are widely used to encapsulate
hydrophobic drugs to increase their solubility.
Polymer based nanoparticles are colloidal carrier systems prepared from
polymers. Polymer materials have been used for several aspects such as encapsulating
active substances to improve their physiochemical characteristics, providing controlled
release, and facilitating drug delivery through multiple administrative routes. Some of
polymers are biodegradable and biocompatible, thus provide sustained drug release while
minimizing skin irritation. The most commonly studied biodegradable polymers include
poly-(lactic-co-glycolic acid) (PLGA) and poly(ɛ-caprolactone) (PCL). The polymeric
nanoparticles are able to control drug release, increase drug adhesivity in the skin

•Ethosomes
•Solid lipid
nanoparticles

•Micelles
•Niosomes
•Nanoemulsions

Polymer based systems

Lipid based systems

•Liposomes

Surfactant based systems

therefore becoming an important strategy to control drug delivery into the skin [79, 80].

Figure 1.10 Classification of nanocarriers used for skin applications

•Dendrimers
•Biodegradable
and nonbiodegradable
nanoparticles
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1.8.3 Physical enhancement
Active methods to enhance skin delivery can be adopted when rapid drug action
or macromolecular drug transportation are the main concern. This technique increases
drug transportation through physical disruption of the skin barrier using various principles.
Iontophoresis is a physical technique that applies a small electric current (0.5
mA/cm2) to the skin, which provides the driving force needed for the penetration of
substances. The transdermal transport is caused by direct electrophoresis and
electroosmotic diffusion. The electrode with the same charge as the penetrant is placed
above the drug reservoir and the repulsion of equally charged molecules facilitates the
drug transportation [81, 82]. Electroporation uses a large voltage (50 – 1500 V) for a short
period of 10 ms to 100 ms. The high current produces temporally pores where drugs can
pass through [83].
Sonophoresis (phonophoresis) enhances transport of molecules under the
influence of microwaves (300 MHz – 300 GHz) or ultrasound (20 kHz – 16 MHz). The
enhanced percutaneous absorption of drug molecules is mediated by thermal and nonthermal effects. Ultrasound-induced skin heating causes fluidization of SC lipids along with
non-thermal effect by creating pressure variation in the SC surface or acoustic cavitation.
Gas bubbles are formed and subsequently collapse, leading to the formation of holes in
the corneocytes (enlargement of intercellular space) and disturbance of SC lipids [84].
Microneedles use a small needle (10 – 200 μm length and 10 – 50 μm width)
connected to a drug reservoir and pierces the skin to deliver the drug. Microneedles
enable drug delivery by different mechanisms: (1) forming micro-scale pores as a skin
pretreatment, (2) coating drug onto the microneedle while the drug is dissolved off, (3)
encapsulating drug within a microneedle made from water-soluble or biodegradable
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polymer, and (4) diffusing the formulation into the skin through the needle pores (Fig 1.11)
[85, 86].
Iontophoresis

Sonophoresis

Microneedle

Fig 1.11 Physical enhancement methods. Adapted from [75], [82], [86]
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1.9 The effect of physiochemical characteristics of substance on skin delivery
Polymers are becoming more common in the field of drug delivery. A large amount
of literature has demonstrated the use of polymeric nanoparticles in topical treatment of
dermatological diseases since the drugs are delivered directly into the skin. Various
polymeric nanoparticles with optimal size, charge, and hydrophilicity have been designed
to solve several limitations of topical drug delivery.
Roman et al. visualized the distribution of FITC-conjugated non-biodegradable
polystyrene nanoparticles (diameters 20 and 200 nm) across porcine skin. They found
that the nanoparticles preferentially accumulated in the hair follicles opening in a timedependent manner, while the smaller nanoparticles demonstrated highest accumulation
[87]. Kohli et al. investigated the skin penetration of fluorescence latex nanoparticles
(diameter 50, 100, 200 and 500 nm) that were positively charged, negatively charged and
neutral. They found that only 50 and 500 nm negatively charged particles could permeate
the skin. It was believed that the penetration could be enhanced by the large surface of
nanoparticles (small size) or high charge density (large size). Moreover, the repulsive
forces between negatively charged skin lipids, proteins, and negatively charged particles
may reach the threshold to allow temporary channels to open and permit the permeation
through the skin [88, 89].
Venuganti et al. investigated skin penetration of dendrimers and focused on the
influence of dendrimer surface charge and dendrimer generation on skin permeation of
5FU. They found that the drug penetration was enhanced with lower generation of
positively charged dendrimers due to the reduction of skin resistance and interaction with
skin lipid bilayers respectively. The concentration of dendrimers did not reflect the
permeability of 5FU [90]. Yang et al. performed similar studies and found that the neutral
and negative charged dendrimers increased skin permeation. Positive charged
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dendrimers increased skin retention, but reduced skin permeation, whereas the
conjugation with oleic acid increased skin absorption and retention. The difference of
penetration may be because of skin-carrier interactions as well as other formulation
ingredients and vehicles used [91].
Shah et a. evaluated the effect of oleic acid modified polymeric nanoparticles for
the delivery of anti-inflammatory drugs. The in vitro skin permeation was performed and
they observed high retention and increased skin penetration depth when nanoparticles
were surface modified with oleic acid. These were explained by the positive charge of
nanoparticles assisting the binding of SC; oleic acid hydrates skin and disturbs lipid
bilayers of SC, thus facilitating the permeation of the drug into deeper layers of skin. The
reduction of dermatitis response was enhanced by drug combination, nanoparticle
formulation, and surface modification with oleic acid [92, 93].
A number of researchers investigated topical drug delivery in experimental
psoriatic mouse model as well. Yin-Ku et al. evaluated the influence of psoriasis-like
condition on the cutaneous permeation of four anti-psoriatic drugs (5-aminolevulinic acid,
tacroimus, calcipotriol, and retinoic acid). They found that the most hydrophilic molecule
showed the greatest skin deposition and flux, caused by the deficient resistance of
epidermal barrier in psoriatic skin [94]. Sun et al. encapsulated curcumin into PLGA
nanoparticles and tested it in a psoriasis mouse model. They found that nanoparticle
carriers enhanced drug penetration and the smaller particles demonstrated higher
penetration into psoriatic skin which significantly improved anti-psoriatic activity in mice
[95].
The enhancement of skin penetration using a pH-sensitive liposome was reported
by Tokudome et al. The negatively charged liposome that was designed to be sensitive in
acidic conditions (pH 5) increased skin delivery of hydrophilic drugs performed by vertical
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diffusion cells. This was caused by the ability to fuse with cell membranes while the
instability, in response to pH change, subsequently released the entrapped drug [96].

1.10 Statement of the problem and the hypothesis
Topical delivery of PAMD for the treatment of psoriasis
This study served as an initial evaluation of polymeric AMD3100 (PAMD) drug that
may be useful for a topical treatment of psoriasis. AMD3100 is a CXCR4 antagonist that
blocks the inflammatory cascades associated with CXCR4/SDF-1 axis. The subcutaneous
injection of AMD3100 demonstrated the reduction in psoriatic conditions related to skin
inflammation and blood vessel angiogenesis. However, this route of administration
generally causes pain and increases side effects related to systemic exposure. Hence,
the topical application with PAMD might be a suitable approach due to several advantages
including non-invasiveness of the procedure, expected long retention in the skin, the ability
to deliver drugs to the diseased site, and minimization of systemic exposure.
In this study, PAMD was delivered locally to the inflamed sites. PAMD is a synthetic
cationic polymer that offers the full function of CXCR4 antagonism along with the
properties to form a nanocarrier, the ability to combine with other drugs, and the ability to
be

custom-synthesized

without

compromising

potency.

PAMD

used

here

is

macromolecule with a molecular weight of 15 kDa, thus delivery into the skin is a
challenge. It is well known that the charge, size, and hydrophobicity have a significant
impact on skin penetration behavior. That being said, the existing publications are often
contradictory. In addition to surface chemistry, psoriasis generally presents with
compromised skin barrier function. Therefore providing the possibility for PAMD to reach
the target tissue at a high concentration via topical administration.
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To my knowledge, this is the first study that has demonstrated the effect of PAMD on
psoriatic skin penetration and the in vivo efficacy compared to AMD3100 injectable form.
The hypothesis of this study is:
(1) The hydrophobicity and surface charge play an important role in skin penetration and
influence on the anti-psoriatic activity of PAMD because of the differences in
penetration depth and skin deposition and retention.
(2) The topical formulation of PAMD or PAMD analog would provide a comparable or
better in vivo therapeutic efficacy to AMD3100 injectable form.
In the next chapters, I will present the modification and characterization of PAMD and
PAMD analogs. The in vitro studies of polymers were performed in cell lines and Franz
cells prior to the in vivo therapeutic study. Imiquimod-induced psoriasis in mice was used
as a model for evaluation of anti-psoriatic therapies.
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CHAPTER 2
DESIGN AND SYNTHESIS

2.1 Introduction
In the previous chapter, I outlined the involvement of CXCR4 receptor and its
ligand CXCL12 in psoriasis and how it had been studied and demonstrated to be
upregulated in psoriatic lesions [58]. The inhibition of the axis using AMD3100 (S.C)
accelerated the healing by reducing inflammation and angiogenesis. My lab has worked
on PAMD for several years in regard to cancer therapy, but herein I would like to describe
how PAMD, as a topical formulation, can be used as an anti-psoriatic drug for local
treatment and long-term management.
PAMD is a synthetic, cationic, and polymeric version of AMD3100 capable of
acting as a non-viral gene vector and open to chemical modifications [97]. Furthermore,
the polymer can condense negatively charged nucleic acids into nanosized particles
through electrostatic interaction and facilitate the internalization across cell membranes.
Once inside the cell, PAMD can also protect nucleic acids from nuclease degradation,
thereby enhancing the therapeutic outcome of gene therapies. These qualities were
demonstrated in an in vivo experimental mouse model that showed inhibition of cancer
cell invasion with improved colloidal stability, survivability, and transfection activity. This
shows the modified PAMD demonstrated dual functionality as an efficient gene delivery
tool while maintaining CXCR4 inhibition [59-61].
While PAMD has been shown effective in previous use cases, its size makes
penetrating the skin in a topical formulation a challenge. The focus of my study was to
improve the skin penetration and retain CXCR4 antagonistic activity of PAMD that could
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later translate into a topical formulation for psoriasis. Many research groups have tried to
modify and formulate active macromolecular drugs for efficient dermal delivery. Their
results suggest that the permeability coefficient of topically applied solutes is dependent
on hydrophobicity, size, and charge [67, 91, 92, 98]. Therefore, this chapter focuses on
the chemical modification of PAMD either by increasing content of hydrophobic moiety or
negative charge.

2.2 Materials and methods
Materials
N,N′-hexamethylenebisacrylamide (HMBA) was purchased from Polysciences, Inc.
(Warrington, PA). Free-Base form of AMD3100 was purchased from Shanghai
Biochempartner Co., Ltd (Shanghai, China). Rhodamine B Isothiocyanate, citraconic
anhydride, oleic acid, A, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride
(EDC), N-hydroxysuccinimide (NHS) and 1-octanol were all obtained from Sigma-Aldrich
(St. Louise, MO). Plasmid DNA (gWiz) was purchased from Aldevron (Fargo, ND). Human
SDF-1α was from Shenandoah Biotechnology, Inc. (Warwick, PA). All other reagents and
chemicals used in this study were obtained from Fisher Scientific (Waltham, MA) and used
as received unless otherwise noted.
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2.2.1 Synthesizing Polymeric AMD3100 (PAMD) and fluorescently labelling with
Rhodamine Isothiocyanate (RITC)
PAMD was synthesized by Michael polyaddition of equal molar ratio of AMD3100
and HMBA according to Li et al. [59]. Michael addition reaction was described as a reaction
between nucleophiles and activated alkenes. The reaction enables chain growth
polymerization and has been employed in the synthesis of linear, graft, hyperbranched,
and network polymers [99, 100]. 1 mmol of each reactant was dissolved in a glass
scintillation vial containing 10 mL MeOH/water (7/3 v/v) mixture. Polymerization was
carried out under nitrogen protection in dark at 37 °C for 3 days. Then, additional 0.1 mmol
of AMD3100 was added to the reaction mixture and stirred overnight to consume any
unreacted acrylamides. Product was purified by dialysis (MWCO 3,500) and dried in
vacuum. To conjugate PAMD with RITC, RITC was first dissolved in DMSO and added to
the PAMD solution dropwise under vigorous stirring at RT for 24 h. Unreacted RITC was
removed by dialysis against deionized water for 3 days. The purified product was then
lyophilized and stored at -20 °C, protected from light until use (Fig 2.1).
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Fig 2.1 Synthesis of PAMD and PAMD.RITC
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2.2.2 Preparation of PAMD modified with citraconic anhydride (PAMD.COO -)
The preparation was guided by the Hermanson group [101]. The compound
citraconic anhydride was used to create a negatively charged PAMD because it is
reversible after acylation. To synthesize PAMD.COO - with various degrees of citraconic
anhydride substitution, PAMD was first dissolved in a 0.1 M sodium carbonate (pH 9)
buffer. Then, 10 molar excess of citraconic anhydride to PAMD was added to the reaction.
Multiple additions were done to maintain the solubility of the reagent by adding 1 M NaOH
periodically to keep the pH in the proper range (8-9). Maintaining high pH is necessary
due to the tendency of citraconylamides to hydrolyze at low pH. The reaction was
performed overnight (12 h) at room temperature, purified by dialysis before lyophilization
(Fig 2.2). To remove citraconic modifications and free the amine groups in PAMD, the pH
of citraconylated molecules are adjusted to a lower pH (3-5). PAMD.COO- was dissolved
in 0.1 M phosphate-citrate buffer and stirred at 37 °C for at least 24 h. 1H NMR and CXCR4
redistribution assay were used to verify the reversal of PAMD.COO- into PAMD.
The negative-to-positive charge reversal is caused by a pH shift. Natural skin pH
values are described in acidic range (4-7) [102] and the barrier disruption is associated
with decreased pH value [94]. On this occasion, the cationic PAMD are first masked at the
physiological pH, but once they are exposed to the intrinsic stimuli, the PAMD’s positive
charge is recovered. The positive charge (amine group) is important for the receptor
binding and CXCR4 antagonistic activity of PAMD.
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Fig 2.2 Synthesis and de-blocking amine groups of PAMD.COO-
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2.2.3 Preparation of PAMD modified with oleic acid (PAMD.OA)
The penetration enhancers such as oleic acid (OA) appears to increase skin
permeability, as a result from mechanisms involving both SC lipid fluidization and enhance
permeant partitioning into SC lipid [103]. OA is a monounsaturated fatty acid and a
component of natural fat derived from either vegetable oils or animal fat. OA has been a
traditional (the most popular penetration enhancer) and widely studied fatty acid by the
pharmaceutical industry as a vehicle for delivering actives through the skin [104].
The preparation of PAMD.OA was adapted from Park et al. [105]. EDC/NHS
reaction was used to activate carboxyl groups in oleic acid and facilitate the conjugation
with amine groups in PAMD. 70% ethanol was chosen because PAMD and OA are soluble
in ethanol whereas EDC/NHS requires an aqueous solution. Thus, the co-solvent of
ethanol and water can dissolve all reagents and allow the conjugation to proceed. To
activate OA, 0.1 M NaOH was added to dissolve OA completely, followed by 2 molar
excess of EDC and 2.5 molar excess of NHS. The reaction was stirred at 37 °C for 30
min. In a separate vial, PAMD was dissolved in 70% ethanol mixed with 0.1 M NaOH.
PAMD solution was poured into the activated oleic acid solution and stirred at 37 °C
overnight (12 h). At the end of this reaction, the product was purified by dialysis and dried
in vacuum (Fig 2.3).
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Fig 2.3 Synthesis of PAMD.OA
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2.3 Characterization of PAMD and PAMD analogs
2.3.1.1 Proton nuclear magnetic resonance (1H NMR)
The chemical structure of PAMD (Fig 2.4) conjugated with citraconic anhydride (Fig 2.5)
and PAMD conjugated with OA (Fig 2.6) were confirmed by 1H NMR in DMSO (PAMD
and PAMD-OA) and D2O (PAMD-COO-) using a Varian INOVA (500 MHz, Bruker BioSpin
Corp., Billerica, MA).
2.3.1.2 UV/Vis spectrophotometry
The amount of RITC molecules per PAMD was calculated from UV/VIS measurement
using Multi-Mode Microplate Reader (SpectraMax iD3, Molecular Devices, LLC,
Sunnyvale, CA). Serial dilutions of RITC in 50% methanol-water were prepared and used
to plot the standard curve. The polymers with unknown RITC conjugation were diluted with
the same solvent and quantified using standard curve equation.
2.3.1.3 Gel permeation chromatography (GPC)
The molecular weight of PAMD was analyzed by GPC operated in 0.3 M sodium acetate
buffer (pH 5) using Agilent 1260 infinity LC system equipped with a miniDAWN TREOS
multi-angle light scattering (MALS) detector and a Optilab T-rEX refractive index detector
from

Wyatt

Technology

(Santa

Barbara,

CA).

Polycation-compatible

TSKgel

G3000PWXL-CP column (Part No. 0021873, Tosoh Bioscience LLC, King of Prussia, PA)
was used at a flow rate of 0.5 mL/min. The result was analyzed using Astra 6.1 software
from Wyatt Technology. The molecular weight of PAMD analogs were calculated based
on the determined molar mass of PAMD using GPC. The citraconic or oleic acid
substitution degree was determined from the 1H NMR (Fig 2.7), (Table 2.1).
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Fig 2.4 1H NMR characterization of PAMD.RITC. The aromatic protons (1-4) of AMD3100
appear at 7.0-7.5 ppm.
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Fig 2.5

1

H NMR characterization of PAMD.RITC.COO-. The content of citraconic

anhydride substitution was determined from integral intensity of citraconic anhydride
proton (5) at 5.7 ppm and aromatic protons of AMD3100 at 7.3 ppm.
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Fig 2.6 1H NMR characterization of PAMD.RITC.OA. The content of oleic acid was
determined from integral intensity of oleic acid proton (5-6) at 5.3 ppm and aromatic
protons of AMD3100 at 7.3 ppm.
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Figure 2.7 Chromatogram of PAMD and PAMD.RITC expressed as a relative value to dRI
and UV. The conjugation with RITC increased the size of PAMD as observed by the
decreased retention time. The presence of RITC is confirmed by the positive UV
absorbance signal in the chromatogram.

40
Table 2.1 Characterization of PAMD and PAMD analogs

MW (g/mol)

Mol of RITC
per PAMD2

Mol of
Citraconate
per PAMD3

Mol of Oleate
per PAMD3

PAMD

18090

0.21

0

0

PAMD.COO-.1

18770

0.05

1

0

PAMD.COO-.2

20230

0.07

1.5

0

PAMD.OA.1

18140

0.13

0

0.15

PAMD.OA.2

19450

0.14

0

0.34

Polymer*

1

Calculated

Determined by GPC, 2 Determined by UV/VIS, 3 Determined by NMR

*All polymers were RITC labelled, from now on I will use the word PAMD for PAMD.RITC,
PAMD.COO- for PAMD.RITC.COO- and PAMD.OA for PAMD.RITC.OA
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2.3.2 Partition coefficient determination
The shake-flask method was used to measure partition coefficient of polymers.
The equal volume of 1-octanol and PBS (pH 7.4) were mixed together and shaken for 24
h at RT to mutually saturate two phases. The phases were allowed to separate overnight
and were collected individually. The water-soluble polymers PAMD.COO- and PAMD were
dissolved at a concentration of 1 mg/ml in PBS saturated 1-octanol and PAMD-OA was
dissolved in 1-octanol saturated PBS. PBS and 1-octanol phase were mixed in 3 different
ways (1:1, 2:1 and 1:2 (v/v)) in a separate tube. The tubes were placed on a shaker
overnight and centrifuged at 1000 rpm for 5 min. The fluorescence of the PBS phase was
read using Multi-Mode Microplate Reader (SpectraMax iD3, Molecular Devices, LLC,
Sunnyvale, CA) at 515 nm excitation and 585 nm emission wavelengths. The amount of
polymer in PBS phase was calculated based on the standard curve of fluorescent
intensities versus serial dilutions of a polymer in PBS phase. The partition coefficient (P)
is defined as [1-octanol]/[water] and usually given in the form of its logarithm to base 10
(log P). Log P represents the affinity of a molecule for a lipophilic environment (Fig 2.8).
The value greater than zero suggests the lipophilicity of the polymer (PAMD.OA).
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Fig 2.8 Partition coefficient of PAMD and PAMD analogs
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2.3.3 DNA complexation assay
Electrophoresis using low melting 0.8 % agarose gel was carried out to determine
the feasibility of incorporation plasmid DNA into polymers. The successful condensation
caused by the positively charged whereas negatively charged will not be able to complex
with the DNA due to same charge repulsion. Polymer/DNA polyplexes were formed by
mixing PBS (pH 7.4) solution of DNA and polymer at various polymer/DNA ratios (1
corresponds to w/w of polymer per DNA of 1) to give a final DNA concentration of 20 ug/ml
in polyplexes. The polyplexes were mixed by vigorous vortexing for 15 sed. followed by
incubation at RT for 30 min. Polymer/DNA polyplexes were then loaded onto an agarose
gel containing 0.5 ug/ml ethidium bromide and run under a constant voltage of 120 V in
0.5X Tris/Borate/EDTA (TBE) buffer for 1 hr. The migration of DNA was visualized under
UV transilluminator at a wavelength of 365 nm. The figure below demonstrated that only
PAMD (2.5:1) and PAMD.OA (5:1) were complexed with DNA, presumably due to their
positive rich charge. The greater amount of PAMD.OA was required for condensing the
same amount of DNA, indicating the conjugation with oleic acid hindered the positive
charge of PAMD. On the other hand, the modification with citraconic anhydride converted
the charge to negative and unfolded DNA upon mixing (Fig 2.9).

Fig 2.9 DNA Entrapment efficacy of PAMD and PAMD analogs in agarose gel
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2.3.4 CXCR4 antagonistic activity
CXCR4 antagonism of the polymers was determined by CXCR4 redistribution
assay according to the manufacturer’s protocol [106]. The binding between CXCL12 and
CXCR4 not only induces downstream signaling cascade but it also stimulates the
endocytosis of the CXCR4 receptors. This assay monitors cellular translocation of GFPCXCR4 receptor in response to the stimulation with CXCL12. The CXCL12 stimulated cell
was suggested by the internalization of GFP inside the cells (Fig 2.10).
Recombinant human epithelial osteosarcoma U2OS cells stably expressing
human CXCR4 receptor fused to the N-terminus of enhanced green fluorescent protein
(EGFP) were purchased from Fisher Scientific. U2OS cells were cultured in DMEM
supplemented with 2 mM L-Glutamine, 10% FBS, 1% Pen-Strep and 0.5 mg/ml G418 and
seeded at a density of 8,000 cells/well in a 96-wells black plate with optical bottom. After
24 h, cells were washed twice with 100 μL assay buffer (DMEM supplemented with 2 mM
L-glutamine, 1% FBS, 1% Pen-Strep, and 10 mM HEPES) and incubated with serial
dilutions of various polymers, or AMD3100 in the assay buffer containing 0.25% DMSO at
37 °C for 30 min. Then, SDF-1 was added into each well to make a final concentration of
approximately 10 nM and incubated for 1 hr. Cells were then fixed with 4%
paraformaldehyde at RT for 20 min and washed 4X with PBS. The receptor internalization
was measured using Cellomics ArrayScan V T1 Reader and SpotDetectorV3 BioApplication
software (Thermo, USA). The percent of CXCR4 antagonistic activity was calculated
relative to the positive (300 nM AMD3100) and negative (0.25% DMSO) controls, and the
results were expressed as mean % inhibition ± SD.
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Unstimulated cell: CXCR4-EGFP
localized in the membrane

Stimulated cell: CXCR4-EGFP
is internalized in endosomes

Inhibited cell: CXCR4-EGFP
localized in the membrane

Fig 2.10 The internalization of receptors was induced by SDF-1 but inhibited by CXCR4
antagonism compound. CXCR4 antagonistic activity was expressed by the reduction of
green fluorescence signal

CXCR4 antagonist activity (%)

45

PAMD.COO-.1

120

PAMD.COO-.2

100

PAMD.OA.1

80

PAMD.OA.2
PAMD

60
40
20
0
0.5

1

2

PAMD Concentration (ug/ml)

Fig 2.11 CXCR4 antagonistic activity of PAMD and PAMD analogs
CXCR4 antagonistic activity of PAMD was nearly 100% at the concentration as
low as 0.5 ug/ml. The strong CXCR4 antagonistic properties observed in PAMD were
caused by the specific electrostatic binding of positive charged PAMD to the negatively
charged binding site of CXCR4 receptor. The conjugation with oleic acid reduced CXCR4
antagonistic activity of polymers as the positive charge was neutralized, but the activity
increased as the concentration increased. Meanwhile, the negative charge reduced
CXCR4 antagonistic activity by losing its ability to competitively bind CXCR4 receptors
with SDF-1 and was not concentration dependent (Fig 2.11).
To prove the charge conversion properties of PAMD.COO - or the removal of
citraconic groups. PAMD.COO- was incubated in 0.1 M phosphate citrate buffer pH 3, 4,
and 5 at 37 °C for 72 hours. 1H NMR characterization and CXCR4 antagonist assay were
tested.
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Fig 2.12 1H NMR characterization and CXCR4 antagonist assay of PAMD.COO - at a
different incubation time in 0.1 M phosphate citrate buffer (pH 3)
The peak of citraconic anhydride proton (5.8 ppm) was reduced upon incubation
time, along with the disappearance of green fluorescence in U2OS cell line (Fig 2.12). The
results demonstrated the successful conversion of PAMD.COO - into PAMD in response
to pH change.
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Fig 2.13 CXCR4 antagonist activity of PAMD.COO- at different pH
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Fig 2.14 Cytotoxicity of PAMD.COO- polymers in U2OS cell line
CXCR4 antagonistic activities were tested from individual samples at a final PAMD
content of 2 ug/ml. The above results indicated the conversion of PAMD.COO - into PAMD
occurred in acidic condition (Fig 2.13) and the polymers expressed CXCR4 antagonistic
activities without compromising cell viability (Fig 2.14).
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CHAPTER 3
IN VITRO CELL STUDIES OF PAMD AND PAMD ANALOGS

3.1 Introduction
The experimental models (cell lines, laboratory animals and three-dimensional
skin model) let us imitate separate aspects of the pathological process under controlled
conditions when studying psoriasis. This approach became irreplaceable in preclinical
studies of new medicines, especially in drug screening. The use of established cell lines
offers several advantages including low cost, readily availability in unlimited quantity,
independence from donor variations, access to multiple passages, and cryopreservation.
Moreover, the reproducibility and consistency allow us to identify variables and specific
mechanisms that occur in primary cells.
Psoriasis is a disease driven by the aberrant interactions between epithelium and
the immune system. The proinflammatory cytokines, such as TNF-α, IFN-γ, and IL-17
secreted by immune cells activate epidermal keratinocytes. The activation initiates
changes in their terminal differentiation program and increase their proliferation rate. Antipsoriatic drugs can therefore target either the keratinocytes or the immunocytes.
Keratinocyte proliferation is one of the hallmarks in psoriatic lesions and can be
mimicked using the HaCaT cell line. HaCaT cells, the immortalized human keratinocytes,
are often used as a cellular model for psoriasis [107, 108] and the compounds that inhibit
keratinocyte proliferation potentially used as anti-psoriatic agents. HaCaT cells were
developed from a long-term primary culture of adult human skin keratinocytes [109]. The
cells are easily cultured, immortal (>140 passages), and do not require additional
supplements such as growth factors in the culture medium. HaCaT cells are non-
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tumorigenic, so their transplantation to lab animals does not cause solid tumors, but they
do exhibit parakeratosis (incomplete maturation of epidermal keratinocytes) which is one
of the manifestations of psoriatic skin. These cells also differentiate normally and express
common epidermal markers shown in vivo. However, HaCaT cells have some limitations,
such as a decreased proliferation rate in response to TNF-α, IFN-γ, and IL-17 [110], which
makes them unable to synthesize lipids that are necessary for proper skin barrier
formation [111].
The HaCaT cell line is closely related to normal keratinocytes presented in skin
and thus offer a suitable model to study regulatory mechanisms in the process of human
epidermal cell differentiation and proliferation. In addition, HaCaT cells have been used in
pharmacologic [112] and cutaneous toxicity studies [113, 114]. After keratinocytes are
exposed to toxic compounds, they upregulate series of pro-inflammatory cytokines. These
contribute to increased reactive oxygen species production and activate multiple
immunocytes, resulting in inflammatory responses such as eczema and other skin
diseases [115].
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3.2 Cell culture and cell viability determination
3.2.1 Cell culture
HaCaT cells, a spontaneously transformed human epithelial cell line from adult
skin, were provided courtesy of Dr. Keith R. Johnson, Department of Biochemistry and
molecular biology, UNMC. Cells were grown in tissue culture flask (75 cm2) at 37 °C under
a humidified atmosphere of 95%CO2/5%O2. The cell growth medium comprised
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with L-glutamine, 10% FBS,
and 1% antibiotic Penicillin-Streptomycin solution (penicillin 5000 U/ml and streptomycin
0.1 mg/ml). The cells were harvested by trypsinization (5 min in 0.25% trypsin-EDTA)
when reaching 80% confluency and sub-cultured every three days.

3.2.2 Cell viability determination
Cell toxicity of the polymers was evaluated by CellTiter-Blue® cell viability assay.
HaCaT cells were seeded at a density of 8,000 cells/well in a 96-well plate. After 24 h, the
medium was replaced by 150 μL serial dilutions of polymer in serum-containing medium
before returning the cells to the incubator for 24 h. Polymer solutions were aspirated and
replaced by a mixture of 100 μL serum-free media and 20 μL of CellTiter-Blue® reagent
(CellTiter-Blue® cell viability assay, Promega) then incubated for 1 h. The fluorescence
was read using spectraMax®M5e Multi-Mode Microplate Reader at 560 nm excitation and
590 nm emission wavelength. The relative cell viability (%) was calculated as
[F]sample/[F]untreated × 100%. The IC50 was calculated as polymer concentration
causing 50% inhibition of cells growth relative to untreated cells using a built-in doseresponse analysis in GraphPad Prism.
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Fig 3.1 Cytotoxicity studies of polymers in HaCaT and U2OS cell lines. Each value is
represented as mean ± SD (n=3)
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Table 3.1 IC50 value of polymers using built-in curve fitting procedure in GraphPad Prism

PAMD

PAMD.COO-.1

PAMD.COO-.2

PAMD.OA.1

PAMD.OA.2

HaCaT
(μg/ml)

16.8

> 60

> 60

21.3

22.0

U2OS
(μg/ml)

4.7

> 60

> 60

15.7

13.5

Percentage cell viability was measured as shown in Fig 3.1 and the IC 50 values
of polymers were calculated in Table 3.1. PAMD demonstrated the highest cell cytotoxicity
in both HaCaT and U2OS cell lines. Whereas PAMD.COO - groups did not show the same
level of cell killing activity when various of concentrations were tested, indicating their
biocompatibility on tested cell lines. The keratinocytes toxicity was likely caused by the
highly positive charge of PAMD, as the shielding of amine groups by oleic acid (PAMD.OA)
decreased toxicity. Positively charged polymers demonstrated higher toxicity by
enhancing cell internalization and disrupting membrane integrity [116, 117].
In many cases, higher cell killing activity is an evidence of the possibility to inhibit
cell proliferation in psoriasis. But it also may demonstrate high cutaneous toxicity and
promoting skin disease as well. So, doubt remains that PAMD’s exhibited toxicity or
therapeutic effect is preferable for psoriatic skin. Similarly, the compound that does not
appear to cause toxicity may not illustrate the potential for psoriasis management.
Therefore, the in vivo study should be conducted in order to support this assumption.
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The positively and negatively charged polymers were compared with AMD3100, a
small molecule and active compound used for PAMD polymerization reaction. The
following results indicated that cell toxicity was charge and size dependent (Fig 3.2).
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Fig 3.2 Cytotoxicity of PAMD polymers in HaCaT cells. Each value is represented as mean
± SD (n=3).
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3.3 Permeation of polymers through reconstructive human model
The assessment of percutaneous absorption of molecules is an important step of
topical drug development and should be done using standard experimental models for the
prediction of successful skin delivery. Reconstituted human epidermal (RHE) model is
recommended in OECD test guideline 428 (skin absorption: in vitro method) and served
as a suitable model as an alternative to human skin for the assessment of skin permeation
and penetration in vitro [118, 119]. RHE culture model is the growth of epidermal
keratinocytes at an air-liquid interface. The keratinocytes can differentiate and stratify to
mimic the morphology of normal epidermis. The use of RHE is a suitable method to
minimize the variation between different skin samples. The similarity of tissue architecture
and lipid composition to human skin offer the advantages in dermal penetration studies
even though artificial skin tends to have higher penetration rate than original skin.
EpiDerm™ permeation studies
The EpiDerm™ skin model (EPI-212-X) was purchased from MatTek Corporation
(Ashland, MA, USA) and used within 3 days of delivery. The tissue consists of normal,
human-derived epidermal keratinocytes (NHEK) which have been cultured to form a
multilayered, highly differentiated model of the human epidermis (7-10 cell layers, 75-100
μm thick). The tissue was incubated for 1 hour at 37 °C supplied with 5% CO 2 prior dosing
with 200 μl of polymer solution (150 μg/ml). Tissue was incubated with polymer for 9 hours,
washed with PBS, incubated in 10% Formalin for 20 min at room temperature, and washed
again with PBS with gentle agitation. To image the penetration depth, the tissue insert was
cut and mounted onto a confocal dish, placed top side of the tissue down on the glass.
The penetration was imaged to a depth of 30 μm and the fluorescence intensity of each
layer was measured individually using confocal laser scanning microscopy (Leica, Buffalo
Grove, IL)
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Fig 3.3 Penetration of PAMD and PAMD analogs in Epiderm™ skin model
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From the results, all polymers showed highest intensity at the depth of 10 μm,
indicating they were collected in SC region (Fig 3.3). This skin model is a reconstruction
of normal human epidermis and the permeation behavior was found to correlate with
barrier function. The high molecular weight substances have difficulty penetrating the skin.
Thus, without the damaged skin condition and the modification of molecules, these
polymers will be restricted to SC layer and unable to affect the lower layers due to the
tightly packed dead skin cells. However, it is difficult to conclude that PAMD penetrated to
a higher degree than PAMD.COO- or PAMD.OA due to the fluorescent signal being
unequal among the polymers (PAMD > PAMD.OA > PAMD.COO-) (Table 2.1), the same
pattern was clearly observed in Fig 3.4. The deeper region might have PAMD.COO- but it
was lower than the detection limit.
The in vitro percutaneous permeation studies using mouse skin would be a good
alternative to human skin to observe the penetration behavior in healthy and psoriatic skin
during the initial development of novel compounds. The animal model is more feasible,
relatively low cost, readily available, and can resemble this disease. A wide range of
animal models have been developed and optimized for testing skin absorption for skin
delivery, and are validated to show that they accurately reflect in vivo.
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CHAPTER 4
EX VIVO SKIN PENETRATION STUDIES

4.1 Introduction
During the development of a suitable topical formulation, the most important
parameter for characterizing penetration behavior is the diffusion profile of the active
ingredient. The most frequently used diffusion device for evaluating cutaneous delivery of
drugs ex vivo and in vivo is the franz cell (Fig 4.1).

Fig 4.1 Franz cell used for the determination of skin penetration. It consists of two
compartments: donor and receptor, between which the excised skin is mounted.

4.2 Franz cell protocol
The psoriatic skin-like mouse model was developed and used. Mice were shaved
on their dorsal area (approx. 5 cm 2) and treated with 65 mg of IMQ cream (Perrigo®) for
10 days. Mice were then euthanized and the dorsal skin was collected. The skin was
carefully examined for any defects and the fat and subcutaneous tissues were gently
removed using a surgical scalpel. Afterward, the skin was wrapped with aluminum foil,
sealed in a bag, stored at -20 °C, and used within 2 months.
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The skin was thawed and washed with PBS (pH 7.4) prior to mounting on Franz
diffusion cell set up (Permegear Inc., Riegelsville, PA). The SC side of the mouse skin that
was exposed to polymer solution in the donor chamber was 0.64 cm 2 and the receiver fluid
volume was 5 ml. Each fluorescently labelled polymer was dissolved in ethanol and PBS
50:50 (v/v) with a concentration of 7.5 mg/ml. 200 μl of polymer solution was added to the
donor compartment and was covered with parafilm to prevent evaporation. The skin
permeation study was performed using 3 diffusion cells. The receiver compartment was
filled with PBS and stirred at 300 rpm. The temperature of receiver compartment was
maintained at 37±0.5 °C to simulate the skin temperature at physiological level.
4.2.1 Quantification of polymer skin deposition
After 24 h of skin permeation, the entire dosing area (0.64 cm 2) was collected with
a biopsy punch. Each sample was carefully washed with 3X water followed by 3X ethanol
to ensure the removal of the residual polymer from the skin surface and blotted dry with
lint-free absorbent wipes (Kimwipe). The skin was subsequently cut into small pieces,
added to 300 μl PBS containing 0.1% Tween 20 and homogenized using tissue lyser
(TissueLyser II, QIAGEN) at a frequency of 30/s for 5 min. To this sample, 300 μl of ethanol
was added to enhance polymer solubilization and sonicated using bath sonicator
(Bransonic® CPX Ultrasonic Baths, Branson Ultrasonics Corp., Danbury, CT) for 1 h. The
extracted samples were centrifuged at 12,000 rpm for 30 min and the supernatant were
collected. The fluorescence of the supernatant was analyzed using Multi-Mode Microplate
Reader (SpectraMax iD3, Molecular Devices, LLC, Sunnyvale, CA) at 515 nm excitation
and 585 nm emission wavelengths. The amount of polymer in the skin was then quantified
based on a standard addition method. The known concentrations of polymer were added
to the supernatant and a standard curve was generated of fluorescence intensities versus
concentration of serial dilutions of polymer. All statistical analyses were performed using
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GraphPad InStat (La Jolla, CA). A one-way ANOVA with Tukey-Kramer adjustment was
used for multiple comparisons where appropriate in order to determine significant
differences.
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Fig 4.3 Increased penetration in psoriatic skin when compared with healthy skin
Psoriatic condition enhanced the penetration of polymers (Fig 4.3). The negatively
charged PAMD had the highest skin accumulation in both healthy and psoriatic tissue (Fig
4.2).
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Fig 4.4 The effect of PAMD modification on skin penetration
The SC layer is the outermost layer of skin and functions as a principal barrier to
foreign substances. This barrier is compromised in psoriasis, causing increased skin
permeation. SC is arranged in a brick and mortar like structure. In addition to keratin-rich
corneocytes, the intercellular matrix is made of long chain ceramides, free fatty acids,
triglycerides, and cholesterol. The lipids have a pKa between 4.8 and 6.3 and are
responsible for the net charge of skin. The pH of healthy skin surface is generally acidic
(pH 4-5) and it becomes even lower when psoriasis is formed (pH 3-4). At the low pH of
psoriatic skin, the population of lipids in this region is ionized and has an increased positive
charge, thus increasing the attraction of anionic molecules into the skin. Moreover, high
TEWL was reported in psoriasis, indicating a reduced lipid content in the skin. These
changes in the skin properties also facilitate the penetration of hydrophilic molecules into
psoriatic skin. Epidermis is filled with corneocytes surrounded by aqueous pores and thus
hydrophilic substances can freely move throughout this layer. Fig 4.4 demonstrates that
the modification of PAMD changed skin penetration behavior, the penetrated amount was
pronounced with hydrophilic, negatively charged PAMD.
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4.2.2 Visualization of polymers penetration in skin
Each skin sample was rinsed to remove excess polymer from the surface,
embedded in a tissue freezing medium (OCT™ compound; Tissue-Tek®) and frozen
overnight in a freezer (-20 °C). The frozen samples were sectioned to 10 μm thick slices
using a cryostat (Leica Microtome, Leica Biosystems Inc., Illinois, USA). Skin sections
were imaged using a fluorescent microscope, 10X objective and analyzed using ImageJ
software.
According to the Fig 4.5, weak fluorescent signal was observed in healthy tissue
due to poor penetration across skin barrier. Defective psoriatic skin enhanced the
penetration of the polymers as indicated by a deeper fluorescent penetration signal.
PAMD.COO- groups demonstrated strong fluorescent signal even though they contained
the lowest amount of RITC, while the groups with the highest content of citraconic
anhydride showed a noticeable amount of polymer in a dermal compartment. These
results indicated negatively charged PAMD promoted greater retention and penetration
depth in the psoriatic skin.

62

Fig 4.5 Psoriasis caused weak organization of SC and leaded to the alteration of drug
penetration behavior along with enhanced polymer permeability.
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4.3 Penetration pathway study
The embedded skin was cryosectioned to 10 μm and placed on glass slides. The
slides were air dried, fixed by cold acetone for 5 min, and gently washed using deionized
water. The skin strips were then treated with polymer solutions in a concentration of 1
mg/ml at RT for 1 h. The excess polymer was washed with water and covered with a glass
cover slip. The slides were visualized using a fluorescence microscope.
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Fig 4.6 Skin penetration pathway of polymers
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As described above, there are several penetration routes through the SC. The
internalization or strong interaction between polymer and skin cells lead the polymer to
transport via the intracellular route. Meanwhile, the repulsion or less interaction with skin
cells may facilitate the polymer to follow the intercellular route, thereby allowing rapid
diffusion throughout the skin layers. Cell membranes consist of two sheets of
phospholipids arranged tail to tail. The hydrophilic heads face outward and are abundant
with phosphate groups making them negatively charged. The positively charged polymers
(PAMD and PAMD.OA) preferentially transport via intracellular router due to a strong
charge interactions with cells. In contrast, the negatively charged PAMD.COO- is likely to
be transported via intercellular route because of the limited interactions of the polymer
with the cells (Fig 4.6).
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Fig 4.7 Summary of PAMD penetration mechanism through the skin.
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CHAPTER 5
PSORIASIS MOUSE MODEL

5.1 Introduction
Despite being common in humans, there still is a lack of a suitable animal model
to study psoriasis pathogenesis. Anecdotal reports on spontaneously occurring psoriasislike conditions in monkeys, dogs, and pigs have been published [120], but these
phenomena occurred randomly, therefore excluding them from systematic psoriasis
research. In the past decades, publications of psoriasis animal models have increased
together with a variety of models exploring the pathogenesis (Fig 5.1) [121].

Fig 5.1 Publications related to the pathogenesis and animal models of psoriasis show
increased numbers during 1965 and 2007 [121].
Despite large investments in drug development, the overall success rate of drugs
during clinical trials remain low. Currently, the development of a new drug takes
approximately 20 years to the market and up to 90% of new compounds fail in clinical
phases. The main reason for these failures is the lack of efficacy during phase II and III of
clinical development, which depends on the selected animal model that allows the

66
therapeutic assessment of a specific compound [122]. This indicates a strong need for in
vivo and in vitro models that are reliable, closely resemble human disease, and minimize
time spent in a fiscal manner within the pharmaceutical industry in order to increase
success rates for new drugs being approved.
Mouse models are the most commonly used experimental animal model for
studying human diseases, including psoriasis. Advantages such as controlled breeding
and low costs allow researchers to easily engineer experiments that search for better
treatments and understanding of the fundamental mechanisms of disease. However, there
are several considerable anatomical and physiological differences between human and
mouse, which may influence the phenotype and pathogenesis of disease. For skin, the
epithelium of mice is composed of densely populated hair follicles, whereas human skin
has a much greater interfollicular composition. Mouse epidermis is generally comprised of
2–3 keratinocyte layers with thickness less than 25 μm. Human epidermis is much thicker
(more than 50 μm) but shows slower epidermal turnover. Furthermore, mouse skin
regenerates effectively without significant scarring [123].
The presence of certain types of immune cells causes the difference in antigen
expression pattern and immune response. Mice have several different subtypes of
dendritic cells (DCs) including CD8+ dendritic cells and other inflammatory cells such as
dendritic epidermal T cells (DETCs) and NK 1.1 + T cells that are not found in humans (Fig
5.2). Mice are also inbred, raised under controlled conditions, and genetic models are
usually based on manipulation of a single gene [123].
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Fig 5.2 Skin structure in human and mice. The differences include the thickness of the
epidermis, the density of hair follicles, the differential program of keratinocytes and the
presence of immune cells [3]

5.2 Animal models of psoriasis
There are four main types of in vivo psoriasis animal models and they usually rely on mice
as the host based on the following experimental settings.
Table 5.1 Summary of experimental psoriasis mouse models (adapted from [120], [3,
123-126])
•
1. Spontaneous mutation •
•

1. Flaky skin (fsn)
2. Chronic proliferative dermatitis (cpd)
3. Homozygous asebia (ab)
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These animal models displayed some histological features of psoriasis such as
epidermal thickening, increased dermal vascularity, and infiltration of mast cells and
macrophages. However, the absence of epidermal T cell infiltrate rendered the
immunosuppressive drug (Cyclosporine A), used to treat psoriasis, ineffective. Given
this result, it appears that there is no immunological basis for psoriatic formation in
these models.
•

1. Targeting immune system: K14.p40

•

2. Targeting vascular endothelium: K14.VEGF

•
2. Genetically engineered

3. Targeting epidermal keratinocytes

1. 3.1 Overexpression of the cytokines of interest in the basal
3. 1. Transgenic; a genetic
epidermal layer under the control of promoter keratin-5 (K5)
element
has
been
and 14 (K14): K5.STAT3, K14.IL-6, and K14.TGF-α
introduced
2. 3.2 Overexpression of the cytokines of interest in the
4. 2. Knockout; a genetic
supradermal epidermal layer under the control of promoter
element
has
been
keratin-10 (K10) and involucrin (invol): K10.BMP-6,
removed
Invol.IFNᵧ, and Invol.β1-integrin
•

4. JunB/c-Jun inducible epidermal deletion and IKK2
knockout

Many cytokines have been proposed to play crucial roles in the pathogenesis of
psoriasis. These animal models are designed to modify cytokine expression through
specific promoters, which helps to elucidate the role individual cytokines play in the
pathogenic cascade of psoriasis and the subsequent in vivo effects.
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Based on many observations, only a single cytokine is not sufficient to induce the
complex changes seen in psoriasis. Thusly, it supports the concept of the cytokine
network in psoriasis. The animal models in this group exhibit psoriatic mixed with nonpsoriatic features (alopecia and early lethality).
•
1. Immunological transfer
(Humanized)

•

1. Human T cell transfer: transfer of CD4 +/CD45RBhi into
severe combined immunodeficient (scid) mice
2. Human skin xenotransplantation: implantation of human
psoriatic tissue onto scid mice

These models highlight that psoriasis is an immunological disease mediated primarily
by T-cells and not epidermal keratinocytes. To date, the xenograft model comes closest
to human psoriasis in terms of genetic, phenotypic, and immunopathogenic processes.
Despite that, the difficulties in obtaining human psoriatic skin limits the number of
animal that can be widespread utilized. However, both models are usually employed
for the evaluation of potential therapeutic agents due to human psoriatic drugs (both
small molecules and biologics) demonstrating efficacy in these models.
•

Injection of cytokines: IL-17, IL-23, IL-12

•

Chemically drive: Imiquimod (IMQ)

2. Direct induction

These models are cheap, straightforward, and fast at inducing clinical phenotypes. The
disease progression has been associated with activation of the IL-23/IL-17 axis.

70
Obviously, each psoriasis mouse model possesses its own advantages and
disadvantages. But none of them can completely resemble the pathological features that
occur in humans. Thus, the data from animals should be carefully extrapolated to humans.
Nevertheless, the animal model that is suitable for the study of psoriasis should reflect
many key histological features of the disease such as acanthosis (uniform elongation of
the rete ridges), parakeratosis (retention of nuclei in the stratum corneum), hyperkeratosis
(thickening of the outer layer of skin), microabscesses of inflammatory cells, and scales
[3]. In addition to these criteria, the model should be reproducible, show similar disease
mechanisms to cause psoriasis, as well as be responsive to a therapeutic agent that has
shown efficacy in psoriasis.
Toward this end, the IMQ mouse model was chosen as a psoriasis model in this
study. This animal model forms psoriatic like lesions by external immune activation and
has been increasingly used due to its convenience, cheap, rapid induction, and ability to
closely resemble human psoriasis. Moreover, the model has been useful for the
investigation of anti-psoriatic drugs [93, 94, 127-130].
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5.3 IMQ mouse model [131]
IMQ

is

1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine,

an

imadazoquinoline

derivative, that was originally developed as a low molecular weight nucleoside analog for
the induction of IFNs to provide antiviral activity (Fig 5.3) [132]. Due to its small size and
hydrophobicity, IMQ was suitable to be developed as a topical formulation for the
treatment of external genital and perianal warts [133]. IMQ-induced skin inflammation
model is based on the application of a single synthetic innate Ag receptor ligand and does
not require strong adjuvants like CFA or IFA to activate the immunity leading to the release
of IL-17. In clinical applications, IMQ is a prescription medication that acts as an immune
response modifier that activates immune cells via the toll-like receptor (TLR) 7 [13, 134].
IMQ is generally used for treating genital warts and a number of skin conditions including
superficial basal cell carcinoma and actinic keratosis [135]. Topical use of IMQ for several
weeks can cause psoriasis as a side effect [136]. The induction of cytokines such as
interferon (IFN)-α, IFN-γ and interleukin (IL)-12 will then promote a type 1 T-helper cell
(Th1), or cell-mediated immune response [137, 138]. IMQ-treated mouse skin exhibits
most of the human psoriasis characteristics toward erythema, skin thickening, scaling,
epidermal alterations (acanthosis, parakeratosis), and neoangiogenesis. Along with the
respective to inflammatory infiltrate consisting of T cells, neutrophils, DCs, and pDCs. The
IL23/IL17 pathway is mainly involved in the progression of disease. Therefore, the IMQ
induced psoriasis model is widely accepted as a reliable preclinical psoriasis model and
was used for this study.

Fig 5.3 Chemical structure of Imiquimod (IMQ), a selective TLR 7 agonist

72
5.3.1 Mice and treatment
C57BL/6 female mice at 8 to 11 weeks old were purchased from Charles River
Laboratories and maintained in University of Nebraska Medical Center animal facilities in
accordance with the standards Guide for the Care and Use of Laboratory Animals and the
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). All
animal procedures were approved by the Institutional Animal Care and Use Committee
(IACUC), University of Nebraska Medical Center, NE.
Mice received a daily topical dose of 62.5 mg of commercially available IMQ cream
(5%) on the shaved back for 9 consecutive days. Topical application of IMQ showed
systemic effects in mice. Mice became ill from day 2 as evidenced by decreased appetite,
movement, and weight loss of 18%. These effects might reflect a pyrogenic response
since IMQ application transiently induced high levels of circulating IL-6 in mice [131].
Moreover, we also observed a 3-fold increase in spleen mass reflecting the disease
related immune activation (Fig 5.5).

Fig 5.4 Psoriatic dorsal skin and pH test. Skin thickening, erythema, and scaling are
observed on gross appearance. The skin became more acidic (yellow to orange color)
when tested using pH pencil (Hydrion ® surface pH pencil).
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Fig 5.5 IMQ-treated dorsal skin mice observation

Psoriasis
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5.3.2 Model observation and evaluation
5.3.2.1 Histology of psoriatic skin
Part of psoriatic lesion was harvested, fixed with 10% formalin solution, and
processed for histological paraffin sectioning. The sections were stained with H&E, CD3,
CD31, CD68, and Ki-67 to verify the presence of psoriasis features in IMQ-treated mouse
model.
Analysis of H&E stained section from IMQ-treated skin showed increased
epidermal thickening (Acanthosis). Acanthosis was caused by the hyperproliferation of
keratinocytes as increased numbers of keratinocytes infiltrated the basal layer. Scaling of
the skin is often an indication of parakeratosis, which is an altered epidermal
differentiation. Close examination of H&E stained sections of IMQ-treated mice showed
retention of nuclei in the stratum corneum due to a disturbed epidermal differentiation and
an absent granular layer. The number of T-cells (CD3+), endothelial blood vessels
(CD31+), macrophages (CD68+) in dermal region, and proliferating cells (Ki-67) of basal
keratinocytes were significantly different between healthy and psoriatic groups. The
proliferative activity of the epidermis, angiogenesis, and inflammation seen in the skin
indicated psoriasis (Fig 5.6).

Psoriasis

Healthy

75

H&E

Ki67
(Proliferation)

CD3
(T-cell)

CD31

CD68

(Endothelial)

(Macrophage)

Fig 5.6 H&E staining and immunohistological detection of psoriasis-like mice dorsal skin.
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5.3.2.2 Upregulation of TNF-α and CXCR4 in psoriatic mouse skin
Total RNA was extracted from back skin (isolated after sacrificing the mice) using
Trizol reagent (Life Technologies, Gaithersburg, MD), according to the manufacturers
protocol. cDNA was reverse transcribed from 2 ug of RNA using MultiScribe™ reverse
transcriptase. mRNA level was measured by real-time quantitative PCR analysis using the
Rotor-Gene Q instrument from QIAGEN (Hilden, Germany). The buffer condition used
iTaq™ Universal SYBR® Green supermix kit (2x) and 10 μM of each primer. The
amplification cycle was conducted as follow: initial denaturation at 95 °C for 30 seconds,
then 40 cycles of denaturation (95 °C) for 5 seconds, and followed by annealing (60 °C)
for 30 seconds. mRNA level of cytokines were calculated relative to the amount found in
a control (healthy) sample according to the comparative threshold cycle (Ct) method, and
was corrected for GAPDH mRNA levels to normalize RNA input.
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Fig 5.7 Upregulation of TNF-α and CXCR4 in psoriatic mouse skin.
The IMQ induced changes in cytokine expression and elevated the levels of mRNA
CXCR4 and TNF-α (Fig 5.7). TNF-α, a pro-inflammatory cytokine, is produced by several
cell types in inflammatory processes, including macrophages, keratinocytes, Th1 cells, Th
17 cells and inflammatory DCs [139]. There are evidence that the circulating levels of TNFα are elevated in both blood and psoriasis lesions, and correlate with disease severity
[140]. TNF-α regulates the ability of DCs to activate T cells and induces the expression of
several cytokines and chemokines. Hence, the inhibition of TNF-α is effective in the
treatment of psoriasis [141, 142].
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CHAPTER 6
IN VIVO THERAPEUTIC STUDIES OF TOPICAL CXCR4 POLYMERS IN IMIQUIMODINDUCED PSORIATIC LIKE SKIN MOUSE MODEL

6.1 Introduction
AMD3100 showed promising results in treating psoriasis-like conditions in IMQ
mouse models [58]. AMD3100 blocked the signal between CXCR4, expressed on immune
cells and endothelial cells, and SDF-1 that is secreted by inflamed tissue. Blocking CXCR4
subsequently reduces inflammatory cascades (induced by T cell activation) and the
increased number of blood vessels present in psoriatic lesions. Originally, AMD3100 was
subcutaneously injected, which causes systemic side effects in chronic disease like
psoriasis. Therefore, topical application of a CXCR4 inhibitor would be a good approach
to target the disease locally with minimal systemic side effects.
In the previous chapters, PAMD and PAMD analogs were synthesized and
analyzed. The in vitro cell studies and ex vivo skin penetration studies were then
conducted. We observed the CXCR4 reversible properties, biocompatibility, high
accumulation, and deep penetration of hydrophilic, negatively charged PAMD. These
findings provided us with strong rationale to test anti-psoriatic efficacy of the polymers in
vivo. In this chapter, the in vivo therapeutic studies of PAMD were performed and the
activity was compared with subcutaneous administration of AMD3100 and topical
application of hydrocortisone using IMQ-induced psoriasis in mice.
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6.2 In vivo IMQ-induced psoriatic plaque like model
The model was developed by Fits et al. [143] and has been utilized by a number
of investigators in psoriasis studies. Female C57BL/6 mice [144] were purchased from
Charles River Laboratories at 8 weeks of age and allowed 3 days to acclimate prior to
starting the experiments. Mice were briefly sedated with isoflurane and the back skin was
carefully shaved (4 cm 2) using an electrical razor [145]. Two days later, a topical dose of
3.125 mg IMQ active compound or 62.5 mg of IMQ cream was applied daily to the shaved
back for 5 consecutive days. The mice with inflamed skin were then divided into 5 groups
(3 mice each): vehicle (water-ethanol 50%, negative control), 1% hydrocortisone (positive
control), PAMD (topical solution), PAMD.COO- (topical solution), and AMD3100 (S.C.).
The following treatment doses were given: 1 g/kg/day (PAMD), 10 mg/kg/12h (AMD3100),
and 100 mg/kg/day (hydrocortisone). The treatment was carried out for another 5
consecutive days and mice were sacrificed on day 10 using CO 2 exposure followed by
cervical dislocation (Fig 6.1).

Day 0
IMQ

Day 1
IMQ

Day 2
IMQ

Day 3
IMQ

Day 4
IMQ

Day 5
TX+
IMQ

Day 6
TX+
IMQ

Day 7
TX+
IMQ

Fig 6.1 In vivo experimental design to test anti-psoriatic efficacy of PAMD.

Day 8
TX+
IMQ

Day 9
TX+
IMQ
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6.3 Scoring severity of skin inflammation
To score the severity of skin inflammation, an objective scoring system was used
based on the clinical Psoriasis Area and Severity Index (PASI). Redness, scaling, and
thickening were scored independently from 0 to 4, which was described by Armanda et al
(Fig 6.2) [146]. Skin thickness was measured using digital caliper with the increased
thickness indicating the extent of the inflammation. The score was determined daily and
the cumulative score served to indicate the severity of inflammation (0–12).

Fig 6.2 Psoriasis scaling. Psoriasis Area and Severity Index (PASI) scoring based on (a)
redness and (b) scaling [146].
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6.4 Results and discussion
Mice were weighed before starting the experiment, during the experiment and prior
to sacrifice. The spleens from each mouse were removed and weighed immediately
following sacrifice. The spleen is a sensitive indicator of immune stimulation or depletion.
The increased spleen mass may demonstrate the increased number of cells in the spleen,
which may reflect the immune activation and systemic effects. The spleen was harvested

Spleen mass to body weight ratio

at the end of the experiment and the weight was measured.
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Fig 6.3 Effect of treatment on splenomegaly.
A significant difference in splenomegaly was observed between healthy and
psoriatic groups, but there was no difference among the negative (vehicle), positive
(hydrocortisone), AMD3100 (S.C.), PAMD and PAMD.COO - groups. These results
indicated that the systemic inflammation was not reduced in the experiment (Fig 6.3).
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Fig 6.4 Effect of PAMD treatment on animal body weight, skin thickness and PASI score
in psoriatic mice.
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6.4.1 Gross observation
The topical application of IMQ cream to mouse skin elicits a dermatitis resembling
psoriasis features, including erythema, scaling, keratinocyte proliferation with acanthosis,
parakeratosis, and dermal inflammatory infiltrate. Here, decreased body weight was
observed after the IMQ was applied, but the mice could recover after day 3. The reduction
of body weight might reflect the systemic response to IMQ, which includes dehydration
and decreased activity level.
By judging the PASI score, as expected, the therapeutic efficacy of hydrocortisone
was more pronounced compared to the rest of the treatment groups. We observed that a
local treatment with PAMD and PAMD.COO- contributed comparable anti-psoriasis activity
as subcutaneously injected AMD3100. The PASI scores decreased between from
hydrocortisone to AMD3100, PAMD, PAMD.COO-, and vehicle. AMD3100 (S.C) showed
a more rapid onset than PAMD and PAMD.COO - due to the potency of systemic
administration. PAMD.COO- must be activated in the skin to show its activity, thus requires
longer onset of action than the other groups. The inflammation observed in the vehicle
group was as expected (Fig 6.4) [127, 147].

6.4.2 Histology
The back skin of mice was collected and fixed in 4% paraformaldehyde. The
tissues were submitted to the UNMC tissue core facility for paraffin embedding and
staining with H&E. Additional staining applied was Ki-67, a cellular proliferation marker. A
light microscope equipped with a computer-controlled digital camera was used to visualize
the sections.

84

Fig 6.5 Representative skin sections of treated mice stained with H&E.

Fig 6.6 Representative skin sections of treated mice stained with Ki-67.
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Fig 6.7 Histological evaluation of skin sections was scaled based on four parameters.
IMQ induces psoriatic phenotypes such as the thickening of both the epidermal
and subcutaneous tissue, the thinning of the granular layer along with suprapapillary
thinning of the epidermis, the retention of nuclei in the stratum corneum, and infiltration of
inflammatory cells in the skin.
The

topical

application

of

hydrocortisone,

PAMD,

PAMD.COO-,

and

subcutaneously injected AMD3100 demonstrated relieved inflammation in the IMQ mouse
model as the accumulative histology scores decreased when compared with the vehicle
(Fig 6.7). However, the animals did not completely recovered from the disease as
evidenced by Ki-67 staining. Ki-67 positive staining cells were counted in the basal layer
indicating the keratinocytes were still actively proliferating (Fig 6.6).
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6.4.3 Effect of PAMD on skin inflammatory cytokines
T cells require secondary signals such as interleukins, IFNs and TNF-α to activate
skin inflammatory cascade. The crosstalk between cytokines can also induce other proinflammatory cytokines production and thus prolong the severity and duration of the
disease. In this study, we evaluated the in vivo therapeutic response by measuring effect
of the treatment on mRNA levels of IL-6, IL-1β, TNF-β, and CXCR4 using qRT-PCR.
IL-1 cytokine family is linked to the innate immunity and the mediator in the initiation
and maintenance of psoriasis. Changes in the levels of IL-1 occur upon keratinocyte
differentiation and hyperproliferation and it was markedly increased in psoriasis. IL-1β is
the most studied member because of its role in mediating local and systemic inflammation.
IL-1β is produced by monocytes, macrophages, and dendritic cells in response to TLR
activation [148]. IL-1β is then secreted into the microenvironment and induces the
expression of adhesion molecule on endothelial cells, resulting in the migration of
monocytes and neutrophils to inflamed tissue [149, 150]. The inhibition of IL-1β blocked
Th17 differentiation and reduced psoriasis plaques [150, 151].
IL-6 is a multifunctional inflammatory cytokine that is produced by dendritic cells,
macrophage, monocytes, T cells and keratinocytes in response to a variety of stimuli
including IL-1 and TNF. IL-6 is expressed in high level in psoriasis and contributed to the
keratinocyte proliferation, Th17 differentiation, and tissue inflammation. IL-6 helps to
activate local inflammatory infiltrate (T cells, macrophage, leukocytes), leading to the
severity of psoriasis [152, 153]. IL-6 also correlates with the inhibition of regulatory T cells
(Treg) differentiation. Thus, T memory cells (Tmem) are chronically activated and lead to
the development of psoriasis [154].
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Table 6.1 Primer sequences of mouse genes examined by qRT-PCR
Target gene

Primer sequence

IL-6 forward

ATGGATGCTACCAAACTGGAT

IL-6 reverse

TGAAGGACTCTGGCTTTGTCT

IL-1β forward

CAACCAACAAGTGATATTCTCCATG

IL-1β reverse

GATCCACACTCTCCAGCTGCA

TNF- α forward

GCCCACGTCGTAGCAAACCAC

TNF- α reverse

GCAGGGGCTCTTGACGGCAG

CXCR4 forward

CCTCGCCTTCTTCCACTGTT

CXCR4 reverse

CTGGGCAGAGCTTTTGAACTTG

GAPDH forward

TCCACTGGCGTCTTCAC

GAPDH reverse

GGCAGAGATGATGACCCTTTT

TNF- 
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Fig 6.8 Relative mRNA levels of cytokines in mouse skin treated with different compounds
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IMQ elicited an elevated mRNA level of TNF-α, IL-6, IL-1β, and CXCR4. mRNA
levels of TNF-α, IL-1β, and IL-6 cytokines were decreased by AMD3100 (S.C),
hydrocortisone, PAMD, and PAMD.COO- but were not statistically significant due to the
small sample size. The decrease in CXCR4 might be the consequence of decreased skin
inflammation that led to the reduction of immune cells migrating toward CXCR4 ligands
that are typically produced by inflamed tissue. These results suggested that the
improvement of psoriasis, determined by PASI score and histological evaluation, related
to the reduction of multiple inflammatory cytokines (Fig 6.8). These findings need to be
further validated in a larger group with more signature cytokines of Th1/Th17 (IFN-γ, IL17, and IL-23) as well as a variation in dosages and duration of treatment.
In summary, all treatment groups reduced the inflammation in the IMQ mouse
model of psoriasis. Although hydrocortisone, the positive control in this study, showed
more of an effect, it was not significantly different from the other treatment groups. Topical
application of PAMD and PAMD.COO - provided similar effects as AMD3100 (S.C), but
caused no side effects. PAMD and PAMD.COO- showed comparable outcome, the antipsoriatic activity of these polymers was not dependent on the penetration amount or depth,
but instead relied on the CXCR4 antagonistic activity in the epidermal region.
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CHAPTER 7
SUMMARY

7.1 Overall conclusion
Topical delivery of a polymeric CXCR4 inhibitor PAMD was explored as an
alternative for subcutaneously injected AMD3100 for the management of psoriasis. The
rate and extent of drug absorption in skin depend on the size, charge and composition of
the drug delivery system. In these studies, we synthesized two PAMD analogs with
different charge and hydrophobicity. PAMD and PAMD.COO- are hydrophilic molecules
but PAMD had positive charge and PAMD.COO- had negative charge. PAMD.OA is a
lipophilic molecule with positive surface charge. The conjugation with citraconic anhydride
molecule was selected to make PAMD.COO -. PAMD.COO- exhibited both negative
surface charge and charge conversion properties. The conversion of PAMD.COO - to
PAMD occurred in acidic environment and the rate was dependent on time and pH.
The cellular toxicity was examined in HaCaT human keratinocytes. The unmodified
PAMD caused cell death more than PAMD.OA and there was no cell killing in PAMD.COO . Thus, PAMD.COO- is more biocompatible and potentially will exhibit less skin toxicity
than PAMD. Skin penetration is important in the development of all topical formulations to
predict pharmacological effects and improve formulation. The skin penetration was
performed in Franz diffusion cell for 24 h at physiological conditions. All PAMD polymers
accumulated more in psoriatic skin when compared with heathy skin, a consequence of
the compromised barrier function in psoriatic lesions. The negatively charged polymers
showed the highest skin retention and ability to penetrate into dermis. The penetration
pathway of polymers was also examined. The positively charged polymers showed
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features of intracellular transport, while the negatively charged polymers showed evidence
of intercellular route.
IMQ-induced psoriasis mouse model was used to investigate the in vivo
therapeutic efficacy of PAMD polymers in comparison with hydrocortisone and AMD3100.
Histological examination and cytokine analysis in the skin were performed. We observed
the reduction of skin inflammation in all treatment groups (decrease PASI score,
decreased histological psoriatic score, and decreased mRNA level of pro-inflammatory
cytokines). Interestingly, the topical application of PAMD and PAMD.COO - gave
comparable effect to AMD3100 (S.C).

7.2 Future studies
1. Extend to a larger sample size to reduce the variation within a group.
2. Optimize the dose and treatment duration.
3. Consider using transgenic mice VEGF-K14 for a stable and long term psoriasis model.
4. Improve formulation and therapeutic outcome
•

Combination with other anti-psoriatic treatments that offer the possibility of
synergistic or additive effects.

•

Incorporation into an appropriate base to increase the contact time and improve
skin homeostasis.

5. Combination with physical enhancement methods to facilitate the polymer deposition
in the skin, thus allowing rapid distribution and maintained therapeutic over time.
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